As you might know there are a plenty of investors putting their money on both fronts at the same time. So, naturally if the outcome is either positive or negative for INO, the same guys will likely add or decrease their current position with ONCS. Most are playing ONCS as a second investment to INO, by that I mean they are invested more in INO than ONCS and are convince the ONCS has the potential to explode as well. If you keep tabs of any days when INO goes drastically up or down ONCS will do the same. That I noticed in the past, things have change since the last financing, and it hasn't behaved the same since then. Jmho
Oh yeah, I still have my long term account with ONCS since back in the days Twiz. Like you I am sticking this one out man. Just been really busy these days. Enjoy the time off man @ the beach. See you back @ ONCS land.
Enjoy it Twiz, it's been a long three yrs of fun here. At the beginning it was really bad, but this thing has really turned a corner.
Your missing the point. The market has nothing to do with this dump, albeit very little. Retailers no longer have any pull left after the last $ cash raise, this is becoming the Hulk Hogan of startups. It's the institutional players who are playing with the pps now, investors have becoming the puppets. It's the price you pay when you mortgage your future, money isn't free.
Your absolutely right, they got us by the strings, they are now the puppet masters. Well, its the price we got to pay. Money is not free.
I am afraid your wrong. Retailers do not have the pull to move this BEHEMOTH of a stock now 220 mill outstanding. Yeah, try to move that rock. Hercules would sweat trying to move that one. It's the big guys they are manipulating it for better pricing. Guess they wanted more of a discount than the supposed offered price given by Punit and #$%$ the cash raise. They got us by the balls now! Hold tight and don't hold the bag.
This is what happens when the market losses confidence on how you run a startup. Positive data is no longer enough, we need value. And with the latest cash raise, value has been denied once more. Results, everyone becomes a bagholder!
Gizmo. I am not sure if you are following the Immunotherapy space or not but that space is ramping up and many players like ONCS INO and other big players are positioning themselves to be the first to pioneer in this new area of Oncology medicine. If, Aldo becomes the treatment of choice all these other immunotherapy companies will most likely combine and use Aldo as their medicine of choice to help treat and eliminate most tumors along with their process. This could help propel the PPS to new highs.
Way too low. I would not accept anything South of $50. With 50 mil shares outstanding and a potential world market sales of 3 to 4 bil I would be happy @ $50. Yeah IDIX got $23, MAPP got $24 and this thing is more
valuable and those two any day.
Yeah, that partnership is getting further and further away from reality to be honest. Wishers and hopefuls can dream all they want but this thing is turning out the wrong way. I will also assure you that an RS is more imminent in the near term than that partnership we dream so long about. When I started we only had 50mil shares (about 3.5 years) ago and now this thing won't even budge anymore with decent action. Thanks for pointing out reality as we see it and not wishy washy opinions.
I think going to the IR to get any meaningful info is near impossible. Your better off asking the competition what they think of ONCS, that way you at least will get the some truth out of them. Or best follow writers who wrote about ONCS and see what they think, they at least know more than most retail investors. Don't bother with the IR (high paid secretaries) manning the phone all day. Believe me, all that smiles ain't what it seems.
I agree TAG. But today we are getting our grove back just the way good management should do, respond back immediately to unfounded truths. They are setting a very good example, not to miss with us. LOL
One would be dumber than dumb to have done that. INO did not get where it is for nothing. Those guys have a lineup like no other. Not sure he is trying to share weak hands off that tree or not but wish him luck. I am in both personally but sold half my shares here to go INO a while back, I am long INO and ONCS but trade oncs
Partnership works well if you are competing with others in a tight market, but CYTR has the entire market, it will basically phase doxorubicin and take over from there. Yes, they will have to hire like gangbusters and get their sales team moving fast prior to approval just like
ZGNX did. No need to partner when you got the big house behind you financing your way to market and your KING OF THE HILL.